Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.50 |
| ▸ | JAK1 | P23458 | 7/20 | 0.50 |
| ▸ | ULK1 | O75385 | 7/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | PRKX | P51817 | 1/20 | 0.45 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092960 | 0.88 | JAK2 (0.51) | JAK2JAK1ULK1ROCK2ROCK1 | |
| SCHEMBL4124949 | 0.79 | MTOR (0.55) | JAK2JAK1ULK1ROCK2ROCK1 | |
| SCHEMBL4130093 | 0.76 | AURKA (0.54) | JAK2JAK1ULK1ROCK2ROCK1 | |
| SCHEMBL16564573 | 0.76 | AURKA (0.61) | JAK2JAK1ULK1ROCK2ROCK1 | |
| SCHEMBL4122172 | 0.75 | JAK2 (0.64) | JAK2JAK1ULK1ROCK2AURKA | |
| SCHEMBL4124079 | 0.75 | MAPK1 (0.69) | JAK2JAK1ULK1ROCK2ITK | |
| SCHEMBL16564357 | 0.75 | JAK2 (0.49) | JAK2JAK1ULK1AURKAAURKB | |
| SCHEMBL16564555 | 0.75 | ROCK2 (0.58) | JAK2JAK1ULK1ROCK2ITK | |
| SCHEMBL4118023 | 0.73 | MAPK1 (0.49) | JAK2JAK1ULK1ROCK2ITK | |
| SCHEMBL12907288 | 0.73 | JAK2 (0.61) | JAK2JAK1ULK1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040701-B1 | AMINOINDAZOLE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-03-18 | — | — | EP | claimed |
| US-8207210-B2 | Aminoindazolylurea derivatives | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | claimed |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | SGK2, SGK1, SGK3 | JAK2 174/4885JAK1 78/4885ULK1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.